Prostaglandin-Endoperoxide Synthase 1 Mediates the Timing of Parturition in Mice Despite Unhindered Uterine Contractility

Endocrinology. 2018 Jan 1;159(1):490-505. doi: 10.1210/en.2017-00647.

Abstract

Cyclooxygenase (COX)-derived prostaglandins stimulate uterine contractions and prepare the cervix for parturition. Prior reports suggest Cox-1 knockout (KO) mice exhibit delayed parturition due to impaired luteolysis, yet the mechanism for late-onset delivery remains unclear. Here, we examined key factors for normal onset of parturition to determine whether any could account for the delayed parturition phenotype. Pregnant Cox-1KO mice did not display altered timing of embryo implantation or postimplantation growth. Although messenger RNAs of contraction-associated proteins (CAPs) were differentially expressed between Cox-1KO and wild-type (WT) myometrium, there were no differences in CAP agonist-induced intracellular calcium release, spontaneous or oxytocin (OT)-induced ex vivo uterine contractility, or in vivo uterine contractile pressure. Delayed parturition in Cox-1KO mice persisted despite exogenous OT treatment. Progesterone (P4) withdrawal, by ovariectomy or administration of the P4-antagonist RU486, diminished the delayed parturition phenotype of Cox-1KO mice. Because antepartum P4 levels do not decline in Cox-1KO females, P4-treated WT mice were examined for the effect of this hormone on in vivo uterine contractility and ex vivo cervical dilation. P4-treated WT mice had delayed parturition but normal uterine contractility. Cervical distensibility was decreased in Cox-1KO mice on the day of expected delivery and reduced in WT mice with long-term P4 treatment. Collectively, these findings show that delayed parturition in Cox-1KO mice is the result of impaired luteolysis and cervical dilation, despite the presence of strong uterine contractions.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Abortifacient Agents, Steroidal / pharmacology
  • Abortifacient Agents, Steroidal / therapeutic use
  • Animals
  • Cells, Cultured
  • Cervical Ripening* / drug effects
  • Cervix Uteri / drug effects
  • Cervix Uteri / metabolism*
  • Cervix Uteri / pathology
  • Cyclooxygenase 1 / genetics
  • Cyclooxygenase 1 / metabolism*
  • Female
  • In Vitro Techniques
  • Luteolysis* / drug effects
  • Membrane Proteins / genetics
  • Membrane Proteins / metabolism*
  • Mice, Inbred Strains
  • Mice, Knockout
  • Mifepristone / pharmacology
  • Mifepristone / therapeutic use
  • Myometrium / drug effects
  • Myometrium / metabolism*
  • Myometrium / pathology
  • Ovariectomy / adverse effects
  • Oxytocics / pharmacology
  • Oxytocics / therapeutic use
  • Oxytocin / pharmacology
  • Oxytocin / therapeutic use
  • Pregnancy
  • Pregnancy, Prolonged / drug therapy
  • Pregnancy, Prolonged / metabolism*
  • Pregnancy, Prolonged / pathology
  • Pregnancy, Prolonged / prevention & control
  • Progesterone / metabolism
  • Uterine Contraction* / drug effects

Substances

  • Abortifacient Agents, Steroidal
  • Membrane Proteins
  • Oxytocics
  • Mifepristone
  • Progesterone
  • Oxytocin
  • Cyclooxygenase 1
  • Ptgs1 protein, mouse